Provided by Tiger Trade Technology Pte. Ltd.

Incyte

112.79
+0.04000.04%
Post-market: 112.790.00000.00%19:35 EDT
Volume:1.12M
Turnover:126.77M
Market Cap:22.86B
PE:14.37
High:113.87
Open:112.35
Low:111.81
Close:112.75
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:0.57
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.60
PE(LYR):17.60

Loading ...

Incyte’s Latest Dermal PK Study: What Completed Early-Stage Data Mean for INCY Investors

TIPRANKS
·
10 hours ago

Incyte (INCY) Receives a Buy from Bank of America Securities

TIPRANKS
·
Yesterday

Is Rare Disease Approval Altering The Investment Case For Incyte (INCY)?

Simply Wall St.
·
Yesterday

Incyte price target raised to $114 from $109 at RBC Capital

TIPRANKS
·
Oct 08

Incyte Updates Financial Calendar with Third-Quarter Results Conference Call and Webcast Schedule

Reuters
·
Oct 08

RBC Lifts Price Target on Incyte to $114 From $109, Keeps Sector Perform Rating

MT Newswires Live
·
Oct 08

Knight Therapeutics Wins Brazil Anvisa Approval for Niktimvo to Treat Chronic GVHD

Reuters
·
Oct 06

Knight Therapeutics Announces Regulatory Approval of Niktimvo® in Brazil

THOMSON REUTERS
·
Oct 06

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Xeris Pharmaceuticals (XERS) and Incyte (INCY)

TIPRANKS
·
Oct 06

Incyte Corp. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Oct 06

Stifel Adjusts Price Target on Incyte to $157 From $145, Keeps Buy Rating

MT Newswires Live
·
Oct 05

Incyte Price Target Raised to $157.00/Share from $145.00 by Stifel

Dow Jones
·
Oct 05

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 03

Celcuity Appoints Ex-Incyte CFO David Gryska to Board

Reuters
·
Oct 02

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT

Reuters
·
Oct 02

Incyte Price Target Raised to $128.00/Share from $116.00 by Wells Fargo

Dow Jones
·
Oct 01

Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating

MT Newswires Live
·
Oct 01

Analysts Offer Insights on NA Companies: Micron (MU), Exxon Mobil (XOM) and Incyte (INCY)

TIPRANKS
·
Oct 01

Halozyme Appoints Jim Daly to Board of Directors

Reuters
·
Oct 01